Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: Evaluation of the NULISA targeted proteomic platform in an ethnically diverse cohort
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
INTRODUCTION
Proteomic evaluation of plasma samples could accelerate the identification of novel Alzheimer's disease (AD) biomarkers. We evaluated the novel NUcleic acid Linked Immuno‐Sandwich Assay (NULISA) proteomic method in an ethnically diverse cohort.
METHODS
Plasma biomarkers were measured with NULISA in the Human Connectome Project, a predominantly preclinical biracial community cohort in southwestern Pennsylvania. Selected biomarkers were additionally measured using Simoa and Quest immunoassays and compared.
RESULTS
On NULISA, phosphorylated tau (p‐tau217, p‐tau231, and p‐tau181), glial fibrillary acidic protein (GFAP), and microtubule‐associated protein tau (MAPT‐tau) showed the top significant association with amyloid beta (Aβ) positron emission tomography (PET) status, followed by the neuroinflammation markers C‐C motif ligand 2 (CCL2), chitotriosidase 1 (CHIT1) and interleukin‐8 (CXCL8), and the synaptic marker neurogranin (NRGN). Biomarkers associated with cortical thickness included astrocytic protein chitinase‐3‐like protein 1 (CHI3L1), cytokine CD40 ligand (CD40LG), brain‐derived neurotrophic factor (BDNF), the Aβ‐associated metalloprotein TIMP3 (tissue inhibitor of metalloprotein 3), and ficolin 2 (FCN2). Furthermore, moderate to strong between‐platform correlations were observed for various assays.
DISCUSSION
NULISA multiplexing advantage allowed concurrent assessment of established and novel plasma biomarkers of Aβ pathology and neurodegeneration.
Highlights
-
Classical Alzheimer's disease (AD) biomarkers measured using the NUcleic acid Linked Immuno‐Sandwich Assay (NULISA) with next‐generation sequencing readout (NULISAseq) CNS panel showed strong concordance with those measured using established immunoassay methods from Quanterix and Quest, with glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) exhibiting the strongest correlation.
-
NULISAseq proteomic analysis identified several plasma biomarkers strongly associated with AD pathology in a biracial community cohort of older adults. Notably, phosphorylated tau‐217 (p‐tau217), GFAP, and p‐tau231 displayed the strongest association with amyloid beta (Aβ) pathology, whereas brain‐derived neurotrophic factor (BDNF) was strongly associated with neurodegeneration.
-
We demonstrate that plasma biomarker levels could be influenced by age, sex, apolipoprotein E ( APOE ) genotype, and self‐identified race. Specifically, GFAP, NfL, and surfactant protein D (SFTPD) showed a strong association with age; CD63 and S100 calcium‐binding protein B (S100B) with self‐identified race; synaptosomal‐associated protein 25 (SNAP25) with APOE genotype; and serum amyloid A1 (SAA1) and superoxide dismutase 1 (SOD1) with significant sex differences.
